Polypeptide Multilayer Nanofilms in Drug Delivery - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Polypeptide Multilayer Nanofilms in Drug Delivery
Investigators are exploiting the tremendous structural diversity of polypeptides and their biophysical properties to develop novel drug carriers. Peptide-based materials hold out much promise for tailor-made targeting, penetration, and release of contents in a host of biological microenvironments.

Pharmaceutical Technology

Various carriers have been developed for local or systemic delivery of small-molecule drugs and biologics. The general approaches include liposomes (1–2), copolymer micelles (3), hydrogels (4), microemulsion-based media (5), dendrimers (6), cyclodextrins (7), pectin (8), tocols (9), and synthetic polymer microspheres (10). The materials used to make these carriers are called biomaterials (11). The US Food and Drug Administration, and therefore the entire industry, is shifting increasingly away from poorly-defined biomaterials that may include animal products to highly-defined, animal-component-free biomaterials. Control over structure and origin has long been a selling point of synthetic polymer-based materials for use in vivo. Pertinent concerns in the development of a biomaterial for drug delivery include biocompatibility, efficiency of drug loading, and timescale of drug release. A broad range of methods has been developed to characterize the physical, chemical, and biological properties of biomaterials (12). Some FDA-approved biomaterials lead to side effects in some applications. The breakdown products of poly(lactide-co-glycolide) microspheres, for instance, are highly acidic, lowering the local pH and increasing the severity of inflammation in tissues (13). For such reasons the level of interest in developing novel biomaterials has never been greater.

Polypeptide multilayer nanofilms (PMNs) have recently been developed as multifunctional biomaterials (14). Surprisingly, perhaps, the earliest work on PMNs was for optical coatings (15) and electrochemical electrode coatings (16). It was later proposed to make PMNs out of derivatives of poly(L-lysine) in which "functional" peptides, for example hormone molecules, were grafted onto monomer side chains via the free amino group (17). PMNs are polyelectrolyte multilayer films made largely if not entirely of polypeptides (14).

Polypeptides are interesting for biomaterials development because they are "natural." Peptides constitute half of the dry mass of an organism and they are biodegradable. Moreover, peptides can exhibit extremely high biological specificity and their breakdown products are generally not only benign, but indeed useful as food (18). Furthermore, polypeptides can be designed; an astronomical number of chemically different peptide structures can be realized, and a large number of different peptides can be prepared in huge quantities by various methods (19–20). Peptides designed for PMN fabrication can be protein inspired (21).

Polyelectrolyte multilayer films were first studied systematically by Decher and colleagues (22–23). Polyelectrolytes suitable for multilayer film fabrications can be classified as "strong" or "weak," depending on how they are affected by pH. "Strong" polyelectrolytes show limited dependence on pH, "weak" polyelectrolytes the opposite (24). Polypeptides are weak polyelectrolytes. The isoelectric point of a peptide, the pH at which its net charge equals 0, is a strong function of amino acid composition (25). The author's research group has performed studies to determine how the PMN architecture can be altered with changing pH.

Construction parameters

Figure 1
PMNs are fabricated by electrostatic layer-by-layer self-assembly (LBL). The method is simple and repetitive (see Figure 1). Electrostatic interactions enable and limit polymer adsorption. Electrostatic attraction holds peptides together between layers, and electrostatic repulsion drives peptides apart within a layer. As a result, the researcher can control layer thickness to within about 1–10 nm. The LBL method is versatile. Many different chemical species are suitable. The method is environmentally benign: The most useful solvent for most current applications of LBL is water.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here